Abstract
This article discusses the most significant results of recent studies of various issues of systemic therapy for both early and metastatic breast cancer. The high efficacy of a number of experimental regimens and drugs can serve as the basis for their early introduction into clinical practice. On the other hand, given several possible treatment options in one setting, it is required to search for predictive biomarkers, as well as to determine the most optimal sequence of standard and new therapy regimens.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
